Pharmaceutical Product Monograph: Dexrabeprazole Sodium + Domperidone Capsules
In the pharmaceutical industry, this combination represents a Chiral PPI + Dopamine Antagonist therapy. As a pharmacist and manufacturer, I classify this as a “High-Efficiency Reflux Solution”—it is technically designed for patients who suffer from GERD (Gastroesophageal Reflux Disease) and Dyspepsia where acid suppression and stomach-clearing are both required.
At your WHO-GMP facility in Mumbai, this FDC (Fixed-Dose Combination) is a core Gastroenterology SKU. It is the “refined” successor to the standard Rabeprazole + Domperidone combinations, offering a “cleaner” pharmacological profile.
Therapeutic Profile: Primary Indications
This combination is indicated for the management of acid-peptic disorders associated with impaired gastric motility.
| Indication | Clinical Context | Technical Rationale |
| GERD (Acid Reflux) | Heartburn | Stops the “backwash” of acid into the esophagus and prevents mucosal damage. |
| Non-Ulcer Dyspepsia | Indigestion | Relieves the “heaviness” and bloating felt in the upper stomach after eating. |
| Peptic Ulcers | Gastric/Duodenal | Provides a pH-neutral environment to allow the stomach lining to heal. |
| LPR (Silent Reflux) | ENT / Throat | Reduces acid vapor that causes chronic cough or throat irritation. |
Mechanism: The “Active-Isomer” Advantage
This combination works through two distinct chemical pathways to manage “Stomach Traffic”:
Dexrabeprazole (The S-Enantiomer): This is the active “half” of Rabeprazole. Technically, regular Rabeprazole is a 50/50 mix of mirror-image molecules. By using only the S-isomer, 10 mg of Dexrabeprazole is as potent as 20 mg of regular Rabeprazole. It inhibits the $H^+/K^+\text{-ATPase}$ (Proton Pump) more efficiently, with less metabolic stress on the liver.
Domperidone (The Prokinetic): This is a peripheral dopamine ($D_2$) receptor antagonist. It technically increases the pressure of the Lower Esophageal Sphincter (LES)—the “valve” at the top of the stomach—while stimulating the stomach to empty its contents into the intestine faster.
The Result: Dexrabeprazole turns off the “acid tap,” while Domperidone ensures the stomach is empty, physically preventing reflux from occurring.
The Pharmacist’s “Technical Warning”
The “30-Minute” Protocol: This capsule must be taken on an empty stomach, ideally 30 minutes before breakfast. This allows the Domperidone to start moving the gut before the first meal of the day arrives.
Cardiac Precaution: While safe for most, Domperidone carries a technical risk of QT Prolongation (irregular heart rhythm) at high doses or in elderly patients.
The “Chiral” Benefit: Patients often report fewer headaches and less “brain fog” on Dexrabeprazole compared to older PPIs, as the body isn’t processing the inactive R-isomer.
Drug Interactions: Avoid taking with Ketoconazole or Erythromycin, as these can dangerously increase the blood levels of Domperidone.
The Manufacturer’s Perspective: Technical & Export
From the CEO’s desk at Healthy Life Pharma / Healthy Inc:
The “Efficiency” USP: On your digital marketplace, highlight the “Low Dose, High Potency” nature of Dexrabeprazole. This is a massive selling point for B2B hospital procurement officers looking for modern, science-backed alternatives to legacy generics.
Pelletization Quality: Most of these capsules contain Enteric Coated (EC) pellets of Dexrabeprazole and Sustained Release (SR) pellets of Domperidone. Ensure your Mumbai facility’s coating thickness is strictly validated to prevent “dose dumping” in the stomach’s acidic environment.
Packaging Excellence: Use Alu-Alu blistering. Dexrabeprazole is highly sensitive to moisture; without a superior moisture barrier, the “Chiral” advantage is lost to degradation.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Dexrabeprazole + Domperidone to support your registration in international B2B markets.